BGM Group Ltd. (BGM)

Market Cap	143.56M -92.1%
Revenue (ttm)	47.90M +78.4%
Net Income	-21.18M
EPS	-3.36
Shares Out	13.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,272
Open	9.95
Previous Close	9.96
Day's Range	9.95 - 10.78
52-Week Range	6.45 - 303.00
Beta	1.46
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About BGM

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 12, 2021
• Country: China
• Stock Exchange: Nasdaq
• Ticker Symbol: BGM
• Website: https://www.bgmgroupltd.com

Financial Performance

In fiscal year 2025, BGM Group's revenue was $37.92 million, an increase of 51.09% compared to the previous year's $25.10 million. Losses were -$19.94 million, 1282.1% more than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error